The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
- 1 March 2018
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 141 (3) , 1138-1139.e7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled StudyJournal of Investigative Dermatology, 2015
- Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapyJournal of Allergy and Clinical Immunology, 2013
- Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous UrticariaNew England Journal of Medicine, 2013
- Adaptation and validation of the Urticaria Patient Daily Diary for adolescentsAllergy and Asthma Proceedings, 2012
- Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticariaAnnals of Allergy, Asthma & Immunology, 2012
- Development of a daily diary for patients with chronic idiopathic urticariaAnnals of Allergy, Asthma & Immunology, 2010
- Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposiumJournal of Allergy and Clinical Immunology, 2006
- Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticariaHealth and Quality of Life Outcomes, 2005
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994